Genomic Health (FRA:G7H) Net Income From Continuing Operations : €50.5 Mil (TTM As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Genomic Health Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genomic Health's net income from continuing operations for the three months ended in Sep. 2019 was €17.0 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2019 was €50.5 Mil.

Genomic Health Net Income From Continuing Operations Historical Data

The historical data trend for Genomic Health's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Net Income From Continuing Operations Chart

Genomic Health Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Net Income From Continuing Operations

Get a 7-Day Free Trial

-19.94

-30.58

-13.20

-3.26

22.57

Genomic Health Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Net Income From Continuing Operations	Get a 7-Day Free Trial															10.48	7.83	11.50	14.15	16.97

Genomic Health Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €50.5 Mil.

Genomic Health (FRA:G7H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Penobscot Drive, Redwood City, CA, USA, 94063

Website

http://www.genomichealth.com

Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines